VictoryShares US Discovery Enhanced Volatility Wtd ETF
Limited financial coverage for CSF.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
The VictoryShares US Discovery Enhanced Volatility Wtd ETF endeavors to match the investment returns of the Nasdaq VictoryUS Small Cap 500 Long/Cash Volatility Weighted Index (known as the "Long/Cash Index"), excluding any charges for fees and expenses. Its distinct Volatility Weighting Methodology incorporates both fundamental criteria and volatility as factors in an attempt to surpass the performance of conventional market capitalization-weighted indexing strategies. The underlying Long/Cash Index actively manages market risk by strategically decreasing its equity market involvement during severe downturns, then re-entering when asset prices have either fallen further or recovered.
- IPO
- 2014
- HQ
- San Antonio, TX, US
Get TickerSpark's AI analysis on CSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- 52W High
- $60.63
- 52W Low
- $47.72
- 50D MA
- $53.47
- 200D MA
- $54.26
- Beta
- 0.59
- RSI (14)
- 45
- Avg Volume
- 6.42K
No earnings-call transcripts are available for CSF yet.
- Free Float
- 0.0%
- Shares Outstanding
- 602.07K
- Float Shares
- 0
of shares held by institutions
19 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 99.12K | ▼ 5.65K |
| Cetera Advisor Networks LLC | 40.53K | ▲ 2.68K |
Our CSF coverage
Recent articles, reports, and earnings notes.
No research on CSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CSF report →Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
globenewswire.com · Oct 8
Cerenome Launches CNSide® CSF Molecular Profile Tests
globenewswire.com · Oct 6
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients
gurufocus.com · Sep 30
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
gurufocus.com · Sep 3
Chime Scholars Foundation Announces 2026–2027 Cohort
businesswire.com · Aug 12
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
globenewswire.com · Jul 16
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
gurufocus.com · Jul 14
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
proactiveinvestors.com · Jun 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.